Interference with ERKThr188 phosphorylation impairs pathological but not physiological cardiac hypertrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 18, 2013, Pages 7440-7445

  Ruppert, Catharina ^a,b   Deiss, Katharina ^a   Herrmann, Sebastian ^b   Vidal, Marie ^a   Oezkur, Mehmet ^b   Gorski, Armin ^b   Weidemann, Frank ^b   Lohse, Martin J ^a,b   Lorenz, Kristina ^a,b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Apoptosis; GPCRs; MAPK

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYLEPHRINE; THREONINE;

ANIMAL CELL; AORTA PRESSURE; AORTA VALVE STENOSIS; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; AORTIC VALVE STENOSIS; APOPTOSIS; CARDIOMEGALY; CELL NUCLEUS; CELL SURVIVAL; CYTOSOL; ENZYME ACTIVATION; FEMALE; HEART; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; PHOSPHORYLATION; PHOSPHOTHREONINE; RATS; RATS, SPRAGUE-DAWLEY;

MUS;

EID: 84876924477     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1221999110     Document Type: Article

References (44)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322(22):1561-1566. (Pubitemid 20176696)
2. Kang YJ (2006) Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 34(1):58-66.
3. Diwan A, Dorn GW, 2nd (2007) Decompensation of cardiac hypertrophy: Cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) 22:56-64.
4. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther 128(1):191-227.
5. Rohini A, Agrawal N, Koyani CN, Singh R (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61(4):269-280.
6. Lorenz K, Schmitt JP, Vidal M, Lohse MJ (2009) Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol 41(12):2351-2355.
7. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7(8):589-600. (Pubitemid 44325350)
8. van Berlo JH, Elrod JW, Aronow BJ, Pu WT, Molkentin JD (2011) Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 108(30):12331-12336.
9. Sheikh F, et al. (2008) An FHL1-containing complex within the cardiomyocyte sarcomeremediates hypertrophic biomechanical stress responses in mice. J Clin Invest 118(12):3870-3880.
10. Cheng H, et al. (2011) A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res 109(12):1401-1409.
11. Purcell NH, et al. (2007) Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104(35):14074-14079. (Pubitemid 350003337)
12. Harris IS, et al. (2004) Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110(6):718-723. (Pubitemid 39056272)
13. Punn A, Mockridge JW, Farooqui S, Marber MS, Heads RJ (2000) Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes. Biochem J 350(Pt 3):891-899.
14. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ (2009) A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 15(1):75-83.
15. Vidal M, Wieland T, Lohse MJ, Lorenz K (2012) β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway. Cardiovasc Res 96(2):255-264.
16. Gan XT, et al. (2005) Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes. J Pharmacol Exp Ther 312(1):27-34. (Pubitemid 40096449)
17. Glennon PE, et al. (1996) Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res 78(6):954-961. (Pubitemid 26166703)
18. 2-induced apoptosis. Physiol Genomics 29(2):118-127.
19. Aikawa R, et al. (1997) Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest 100(7):1813-1821. (Pubitemid 27431340)
20. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G (2011) Cell death assays for drug discovery. Nat Rev Drug Discov 10(3):221-237.
21. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270(46):27489-27494.
22. Okada KI, et al. (2004) Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: Possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 110(6):705-712.
23. Baines CP, Molkentin JD (2005) STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38(1):47-62. (Pubitemid 40038651)
24. Kehat I, Molkentin JD (2010) Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 1188:96-102.
25. Herrmann S, et al. (2011) Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol 58(4):402-412.
26. Maron BJ, Pelliccia A (2006) The heart of trained athletes: Cardiac remodeling and the risks of sports, including sudden death. Circulation 114(15):1633-1644. (Pubitemid 44547434)
27. Deschamps AM, Spinale FG (2005) Matrix modulation and heart failure: New concepts question old beliefs. Curr Opin Cardiol 20(3):211-216. (Pubitemid 40704878)
28. Esposito G, et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105(1):85-92. (Pubitemid 34049147)
29. Buitrago M, et al. (2005) The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 11(8):837-844. (Pubitemid 41161115)
30. Heineke J, et al. (2010) CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med 16(8):872-879.
31. Hino A, et al. (2012) Enhanced binding of calmodulin to the ryanodine receptor corrects contractile dysfunction in failing hearts. Cardiovasc Res 96(3):433-443.
32. George CH, Parthimos D, Silvester NC (2012) A network-oriented perspective on cardiac calcium signaling. Am J Physiol Cell Physiol 303(9):C897-C910 10.1152/ajpcell.00388.2011.
33. Pandit B, et al. (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39(8):1007-1012. (Pubitemid 47185177)
34. Muslin AJ (2008) MAPK signalling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115(7):203-218.
35. Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40(10):2023-2039.
36. Yue TL, et al. (2000) Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86(6):692-699.
37. Bueno OF, et al. (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19(23):6341-6350.
38. Lips DJ, et al. (2004) MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109(16):1938-1941. (Pubitemid 38544482)
39. Khokhlatchev AV, et al. (1998) Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93(4):605-615. (Pubitemid 28240721)
40. Scott MG, et al. (2002) Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem 277(40):37693-37701.
41. Tohgo A, et al. (2003) The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 278(8):6258-6267. (Pubitemid 36800882)
42. Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: Involvement in cardiac hypertrophy. Circ Res 91(12):1103-1113. (Pubitemid 36076358)
43. Lorenz K, Lohse MJ, Quitterer U (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426(6966):574-579. (Pubitemid 37522645)
44. Rosenhek R, et al. (2000) Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343(9):611-617. (Pubitemid 30659472)